Search
Cyclizine
go.drugbank.com/drugs/DB01176ApprovedWithdrawnA histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935)
Novobiocin
go.drugbank.com/drugs/DB01051ApprovedInvestigationalVet approvedWithdrawnIn 2009, the FDA determined novobiocin sodium was withdrawn from sale for reasons of safety or effectiveness.[L44062,L43942] … (From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p189) Novobiocin sodium, a salt form of novobiocin, was initially approved in September 1964 and was indicated for the treatment of serious
Synonyms: N-{7-[(3-O-carbamoyl-6-deoxy-5-methyl-4-O-methyl-β-D-gulopyranosyl)oxy]-4-hydroxy-8-methyl-2-oxo-2H-chromen-3-yl}-4-hydroxy-3-(3-methylbut-2-en-1-yl)benzamideMedrogestone
go.drugbank.com/drugs/DB09124ApprovedWithdrawnMedrogestone (INN), also known as 6,17α-dimethyl-6-dehydroprogesterone, is a progestational agent derived from 17-methylprogesterone. It was conceived as an alternative for an orally effective contraceptive option. It was developed by Ay...
Categories: Sex Hormones and Modulators of the Genital SystemAficamten
go.drugbank.com/drugs/DB18490ApprovedInvestigational[L54788] Approved by the FDA on December 19, 2025, aficamten is indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and … [L54783] Aficamten works by attenuating myocardial hypercontractility and left ventricular outflow tract obstruction, which are characteristics of oHCM.[A275293]
Tocainide
go.drugbank.com/drugs/DB01056ApprovedWithdrawnAn antiarrhythmic agent which exerts a potential- and frequency-dependent block of sodium channels.
Products: Tonocard Tab 400 mgCoagulation factor X human
go.drugbank.com/drugs/DB13148ApprovedInvestigationalIt is a two-chain glycoprotein with the molecular weight of approximately 59 kDa [A31472]. … Administration of coagulation Factor X from healthy donor serves to restore and achieve effective hemostasis.
Asfotase alfa
go.drugbank.com/drugs/DB09105ApprovedInvestigationalAsfotase alfa was first approved by Pharmaceuticals and Medicals Devices Agency of Japan (PMDA) on July 3, 2015, then approved by the European Medicine Agency (EMA) on August 28, 2015, and was approved … The annual average price of Asfotase Alfa treatment is $285,000.
Products: STRENSİQ 18 MG/0.45 ML ENJEKSİYONLUK ÇÖZELTİ, 12 ADET, STRENSİQ 28 MG/0.7 ML ENJEKSİYONLUK ÇÖZELTİ, 12 ADETApalutamide
go.drugbank.com/drugs/DB11901ApprovedInvestigationalApproximately 10 to 20 % of prostate cancer cases are castration-resistant, and up to 16% of these patients show no evidence of cancer metastasis at the time of castration-resistant diagnosis [L1295]. … Androgen-deprivation therapy, or hormone therapy, can be used as part of maintenance therapy for patients with non-metastatic prostate cancer.
Products: ERLEADA ®TABLETAS RECUBIERTAS 60 MGAltanserin
go.drugbank.com/drugs/DB19972InvestigationalAltanserin has a monoisotopic molecular weight of 411.14 Da. … The usage of the INN stem '-anserin' in the name indicates that Altanserin is a serotonin receptor antagonist.
Categories: Diagnostic Uses of Chemicals, Compounds used in a research, industrial, or household setting